Furthermore, the dropout-rate in the treatment arm was substantial in the everolimus study and the design of the clinical trials may not have detected all positive effects of mTOR inhibition on ADPKD progression in tubular cells [64,68,69,70]. The gene discussed is MTOR; the disease is autosomal dominant polycystic kidney disease.